Seattle-based company Sana Biotechnology (Sana) received FDA clearance for its Investigational New Drug application aimed at treating “patients with multiple B-cell mediated autoimmune diseases,” according to a company press release.
The drug, SC291, is a cell therapy that operates by repurposing T cells from healthy donors to target B cells, which are known to contribute to the creation of autoimmune diseases in the body. SC291 is specifically designed for patients suffering from lupus (lupus nephritis and extrarenal lupus) and ANCA-associated vasculitis, a group of uncommon autoimmune diseases.
